S&P 500   3,093.34 (-0.74%)
DOW   26,745.06 (-0.79%)
QQQ   214.04 (-1.13%)
AAPL   284.89 (-2.65%)
FB   194.92 (-1.16%)
GOOGL   1,367.74 (-1.63%)
CGC   19.33 (-2.47%)
MU   52.83 (+0.88%)
TSLA   723.94 (-7.05%)
AMD   45.76 (-3.64%)
T   36.65 (-1.21%)
NFLX   388.98 (+2.57%)
BAC   30.26 (-1.21%)
DIS   122.63 (-0.59%)
GILD   73.39 (-1.75%)
S&P 500   3,093.34 (-0.74%)
DOW   26,745.06 (-0.79%)
QQQ   214.04 (-1.13%)
AAPL   284.89 (-2.65%)
FB   194.92 (-1.16%)
GOOGL   1,367.74 (-1.63%)
CGC   19.33 (-2.47%)
MU   52.83 (+0.88%)
TSLA   723.94 (-7.05%)
AMD   45.76 (-3.64%)
T   36.65 (-1.21%)
NFLX   388.98 (+2.57%)
BAC   30.26 (-1.21%)
DIS   122.63 (-0.59%)
GILD   73.39 (-1.75%)
S&P 500   3,093.34 (-0.74%)
DOW   26,745.06 (-0.79%)
QQQ   214.04 (-1.13%)
AAPL   284.89 (-2.65%)
FB   194.92 (-1.16%)
GOOGL   1,367.74 (-1.63%)
CGC   19.33 (-2.47%)
MU   52.83 (+0.88%)
TSLA   723.94 (-7.05%)
AMD   45.76 (-3.64%)
T   36.65 (-1.21%)
NFLX   388.98 (+2.57%)
BAC   30.26 (-1.21%)
DIS   122.63 (-0.59%)
GILD   73.39 (-1.75%)
S&P 500   3,093.34 (-0.74%)
DOW   26,745.06 (-0.79%)
QQQ   214.04 (-1.13%)
AAPL   284.89 (-2.65%)
FB   194.92 (-1.16%)
GOOGL   1,367.74 (-1.63%)
CGC   19.33 (-2.47%)
MU   52.83 (+0.88%)
TSLA   723.94 (-7.05%)
AMD   45.76 (-3.64%)
T   36.65 (-1.21%)
NFLX   388.98 (+2.57%)
BAC   30.26 (-1.21%)
DIS   122.63 (-0.59%)
GILD   73.39 (-1.75%)
Log in

NASDAQ:FATE - Fate Therapeutics Stock Price, Forecast & News

$30.47
-1.41 (-4.42 %)
(As of 02/27/2020 12:57 PM ET)
Today's Range
$29.46
Now: $30.47
$31.28
50-Day Range
$21.70
MA: $26.31
$31.88
52-Week Range
$12.59
Now: $30.47
$32.26
Volume43,379 shs
Average Volume680,628 shs
Market Capitalization$2.30 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.95
Fate Therapeutics, Inc operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FATE
CUSIPN/A
Phone858-875-1800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.74 million
Book Value$2.48 per share

Profitability

Net Income$-66,600,000.00
Net Margins-900.24%

Miscellaneous

Employees104
Market Cap$2.30 billion
Next Earnings Date3/2/2020 (Confirmed)
OptionableOptionable

Receive FATE News and Ratings via Email

Sign-up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.


Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics Inc (NASDAQ:FATE) announced its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by $0.02. The biopharmaceutical company had revenue of $2.43 million for the quarter, compared to analysts' expectations of $1.75 million. Fate Therapeutics had a negative return on equity of 48.94% and a negative net margin of 900.24%. The firm's revenue for the quarter was up 136.7% on a year-over-year basis. During the same period last year, the company posted ($0.31) earnings per share. View Fate Therapeutics' Earnings History.

When is Fate Therapeutics' next earnings date?

Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Fate Therapeutics.

What price target have analysts set for FATE?

16 brokers have issued 1 year price targets for Fate Therapeutics' shares. Their forecasts range from $20.00 to $40.00. On average, they anticipate Fate Therapeutics' stock price to reach $27.06 in the next year. This suggests that the stock has a possible downside of 11.2%. View Analyst Price Targets for Fate Therapeutics.

What is the consensus analysts' recommendation for Fate Therapeutics?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 2 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fate Therapeutics.

Has Fate Therapeutics been receiving favorable news coverage?

Media headlines about FATE stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Fate Therapeutics earned a coverage optimism score of -1.9 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Fate Therapeutics.

Who are some of Fate Therapeutics' key competitors?

What other stocks do shareholders of Fate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), Energous (WATT), Juno Therapeutics (JUNO), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP), Rigel Pharmaceuticals (RIGL), Amarin (AMRN), Immunomedics (IMMU) and Exelixis (EXEL).

Who are Fate Therapeutics' key executives?

Fate Therapeutics' management team includes the folowing people:
  • J. Scott Wolchko, President, Chief Executive Officer & Director
  • Daniel D. Shoemaker, Chief Scientific Officer
  • Yu Waye Chu, Vice President-Clinical Development
  • Jim Beitel, Senior Vice President-Corporate Development
  • Bahram Valamehr, Chief Development Officer

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (9.11%), Victory Capital Management Inc. (5.59%), Victory Capital Management Inc. (4.53%), State Street Corp (3.15%), Franklin Resources Inc. (2.33%) and Jennison Associates LLC (1.73%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc. View Institutional Ownership Trends for Fate Therapeutics.

Which institutional investors are selling Fate Therapeutics stock?

FATE stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Point72 Asset Management L.P., State Street Corp, Victory Capital Management Inc., First Trust Advisors LP, UBS Group AG, Rafferty Asset Management LLC and Citigroup Inc.. Company insiders that have sold Fate Therapeutics company stock in the last year include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker and J Scott Wolchko. View Insider Buying and Selling for Fate Therapeutics.

Which institutional investors are buying Fate Therapeutics stock?

FATE stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., EcoR1 Capital LLC, Marshall Wace North America L.P., Sofinnova Investments Inc., Goldman Sachs Group Inc., Pictet Asset Management Ltd., Schroder Investment Management Group and ARK Investment Management LLC. View Insider Buying and Selling for Fate Therapeutics.

How do I buy shares of Fate Therapeutics?

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $30.47.

How big of a company is Fate Therapeutics?

Fate Therapeutics has a market capitalization of $2.30 billion and generates $4.74 million in revenue each year. The biopharmaceutical company earns $-66,600,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Fate Therapeutics employs 104 workers across the globe.View Additional Information About Fate Therapeutics.

What is Fate Therapeutics' official website?

The official website for Fate Therapeutics is http://www.fatetherapeutics.com/.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]


MarketBeat Community Rating for Fate Therapeutics (NASDAQ FATE)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  391 (Vote Outperform)
Underperform Votes:  258 (Vote Underperform)
Total Votes:  649
MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe FATE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FATE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Featured Article: Percentage Gainers

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel